AU2003289716A8 - Molecules for diagnostics and therapeutics - Google Patents

Molecules for diagnostics and therapeutics

Info

Publication number
AU2003289716A8
AU2003289716A8 AU2003289716A AU2003289716A AU2003289716A8 AU 2003289716 A8 AU2003289716 A8 AU 2003289716A8 AU 2003289716 A AU2003289716 A AU 2003289716A AU 2003289716 A AU2003289716 A AU 2003289716A AU 2003289716 A8 AU2003289716 A8 AU 2003289716A8
Authority
AU
Australia
Prior art keywords
therapeutics
diagnostics
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003289716A
Other versions
AU2003289716A1 (en
Inventor
Srikanth Patury
Edward J Shen
Kristian A Stevens
Darryl Gietzen
Edward S Kirton
Christina M Altus
Robert E Lagace
Xiaobing Shi
Charlyn J Suarez
Mary Kwong
Alan P Au
Martin T Suchorolski
Iqbal S Panesar
Elizabeth A Stewart
Yan Ma
Scott B Anderson
Christopher M Bruns
James Wingrove
Linda V Elder
Thirupathi P Reddy
Toinette A Harthshorne
Bonnie L Hurwitz
Careyna H Peralta
Ursula A Vitt
John L Blanchard
Rachel J Wright
Elizabeth M Mooney
Jr Edward H Gerstin
Fan Shen
Jennifer L Policky
Angelo M Delegeane
Pierre Rioux
Jennifer L Jackson
Mirjana M Marjanovic
Peter A Spiro
Yuming Xu
Xinhao Wang
Mingham C Wu
Scott R Panzer
Jeanette P Schmidt
Laura L Stuve
Steven J Pitts
Steven C Banville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2003289716A1 publication Critical patent/AU2003289716A1/en
Publication of AU2003289716A8 publication Critical patent/AU2003289716A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AU2003289716A 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics Abandoned AU2003289716A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41025902P 2002-09-12 2002-09-12
US41026002P 2002-09-12 2002-09-12
US60/410,259 2002-09-12
US60/410,260 2002-09-12
PCT/US2003/028227 WO2004023973A2 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Publications (2)

Publication Number Publication Date
AU2003289716A1 AU2003289716A1 (en) 2004-04-30
AU2003289716A8 true AU2003289716A8 (en) 2004-04-30

Family

ID=31997928

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003289716A Abandoned AU2003289716A1 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Country Status (2)

Country Link
AU (1) AU2003289716A1 (en)
WO (1) WO2004023973A2 (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2003054141A2 (en) * 2001-10-22 2003-07-03 Children's Medical Center Corporation Sperm-specific cation channel, catsper2, and uses therefor
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20070154886A1 (en) * 2002-12-06 2007-07-05 Macina Roberto A Composition, splice variants and methods relating to ovarian specific genes and proteins
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
EP1615991A4 (en) 2003-04-03 2007-12-19 Bristol Myers Squibb Co Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
WO2004094623A2 (en) * 2003-04-04 2004-11-04 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20060247421A1 (en) * 2003-05-14 2006-11-02 Ko Fujimori Liver x receptor alpha splicing mutant protein, gene thereof and utilization of the same
JP2007531502A (en) * 2003-08-18 2007-11-08 ワイス Novel human LXRα variant
PL1694342T3 (en) * 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
JP4936899B2 (en) * 2003-12-24 2012-05-23 ジー２ インフラメイション ピーティーワイ エルティーディー Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
WO2005076012A2 (en) * 2004-01-30 2005-08-18 Five Prime Therapeutics, Inc. Novel splice variants and methods of use thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
PL1755661T3 (en) 2004-05-12 2014-10-31 Brigham & Womens Hospital Inc Gelsolin for use in treating infections
WO2006008003A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2006008008A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
DK1802749T3 (en) 2004-10-21 2012-11-26 Mayo Foundation KASPP (LRRK2) gene, its preparation and use for the detection and treatment of neurodegenerative disorders
EP1831370A4 (en) 2004-12-13 2009-08-12 Alethia Biotherapeutics Inc Polynucleotides and polypeptide sequences involved in the process of bone remodeling
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene protein encoded therein expression vector containing same and cell transformed by said vector
EP1891234B1 (en) 2005-06-01 2014-12-10 Evotec International GmbH Use of slc39a12 proteins as target in diagnosis and drug screening in alzheimer's disease
EP1739092A1 (en) * 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2014265023A1 (en) * 2005-12-20 2014-12-04 Sbi Biotech Co, Ltd. Anti-ILT7 Antibody
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
EP1964852B1 (en) 2005-12-20 2013-04-17 SBI Biotech Co., Ltd. Anti-ilt7 antibody
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
PT2671954T (en) * 2006-01-20 2018-10-08 Cell Signaling Technology Inc Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20070192885A1 (en) * 2006-01-26 2007-08-16 Daniel Chelsky TAT-039 and methods of assessing and treating cancer
US20070192886A1 (en) * 2006-01-30 2007-08-16 Daniel Chelsky TAT-044 and methods of assessing and treating cancer
WO2007089793A2 (en) * 2006-01-31 2007-08-09 Caprion Pharmaceuticals, Inc. Tat-041 and methods of assessing and treating cancer
WO2007106577A2 (en) 2006-03-15 2007-09-20 The Brigham And Women's Hospital, Inc. Gelsolin in the treatment and diagnosis of neurological disease
PT3279663T (en) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Use of gelsolin to diagnose and treat inflammatory diseases
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
WO2008042814A2 (en) * 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
AU2008275303B2 (en) 2007-07-06 2012-05-03 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
EP2537529B1 (en) 2007-08-02 2018-10-17 Gilead Biologics, Inc. Loxl2 inhibitory antibodies and uses thereof
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
US7892760B2 (en) 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
EP2242770A2 (en) * 2008-01-07 2010-10-27 Patrys Limited Barb4 target which comprises tata-binding protein-associated factor 15, antibody designated barb4, barb4 related antibodies, and methods of making and using same
ES2634263T3 (en) 2008-01-25 2017-09-27 The General Hospital Corporation Therapeutic diagnostic uses of gelsolin in renal failure
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
JP5773650B2 (en) 2008-07-16 2015-09-02 株式会社医学生物学研究所 Anti-human CLCP1 antibody and its use
AU2013202396B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
EP2328911A4 (en) * 2008-09-22 2012-03-14 Cedars Sinai Medical Center Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
CA3013992A1 (en) * 2008-12-30 2010-07-08 Children's Medical Center Corporation Method of predicting acute appendicitis
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
DK3255146T3 (en) 2009-03-16 2019-08-19 Pangu Biopharma Ltd Compositions and Methods comprising Histidyl-tRNA Synthetase Splicing Variants with Non-Canonical Biological Activities
JP4495776B1 (en) * 2009-07-30 2010-07-07 日本製薬株式会社 Fusion protein
AU2010284036B2 (en) 2009-08-21 2014-12-18 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CN103724432B (en) 2009-11-30 2016-06-08 霍夫曼-拉罗奇有限公司 The antibody that the tumour of SLC34A2 (TAT211=SEQID2) is expressed in treatment and diagnosis
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
EP2509625B1 (en) 2009-12-11 2015-01-28 Atyr Pharma, Inc. Histidyl trna synthetases for reducing inflammation
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
NZ623807A (en) 2010-04-13 2016-03-31 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
JP6039546B2 (en) * 2010-05-03 2016-12-07 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of seryl tRNA synthetase
JP6177129B2 (en) * 2010-07-12 2017-08-09 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of histidyl tRNA synthetase
CA2808539C (en) 2010-08-25 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US20130303439A1 (en) * 2010-09-30 2013-11-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
EP2771689A4 (en) * 2011-10-26 2015-06-03 Nuclea Biotechnologies Inc Usp2a peptides and antibodies
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
CA2872467C (en) * 2012-05-01 2019-05-14 Fujifilm Corporation Method of culturing pluripotent stem cell, and polypeptide to be used therefor
CA2926386C (en) * 2012-10-05 2021-11-09 Kadmon Corporation, Llc Human anti-vegfr-2/kdr antibodies
WO2014153195A1 (en) 2013-03-14 2014-09-25 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
ES2708565T3 (en) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugates of Fc-histidyl-tRNA synthetase
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
EP3304082B1 (en) 2015-06-08 2020-05-13 Arquer Diagnostics Limited Methods for analysing a urine sample
US11390656B2 (en) * 2015-08-04 2022-07-19 New York University Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
RU2756109C2 (en) 2016-03-10 2021-09-28 Виела Байо, Инк. Ilt7 binding molecules and their application methods
HUE059159T2 (en) * 2016-04-08 2022-10-28 Immunocore Ltd T cell receptors
WO2018195338A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
SG11202000840YA (en) * 2017-07-31 2020-02-27 Reflection Biotechnologies Ltd Cellular models of and therapies for ocular diseases
KR20200118029A (en) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
GB201803010D0 (en) * 2018-02-26 2018-04-11 Royal Holloway & Bedford New College Neurodegenerative disorders
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
TW202110870A (en) 2019-05-30 2021-03-16 美商葛利史東腫瘤科技公司 Modified adenoviruses
CN111859913B (en) * 2020-06-12 2024-04-12 北京百度网讯科技有限公司 Processing method and device of wind control characteristic factors, electronic equipment and storage medium
CN116438308A (en) 2020-08-06 2023-07-14 磨石生物公司 Multi-epitope vaccine box

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119452A1 (en) * 2000-01-18 2002-08-29 Phippard Deborah J. Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells

Also Published As

Publication number Publication date
AU2003289716A1 (en) 2004-04-30
WO2004023973A2 (en) 2004-03-25
WO2004023973A3 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
AU2003289716A8 (en) Molecules for diagnostics and therapeutics
AU2002344208A8 (en) Molecules for diagnostics and therapeutics
EP1552002A4 (en) Aptamer-toxin molecules and methods for using same
EP1644572A4 (en) Fabric-faced composites and methods for making same
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
EP1638977A4 (en) Salinosporamides and methods for use thereof
HK1088837A1 (en) Clk-peptide and slk-peptide
IL152746A0 (en) Biosensor for molecules
IL172704A0 (en) Salinosporamides and methods for use thereof
GB0301227D0 (en) Seating apparatus
EP1589128A4 (en) Corrosion-resistant member and method for producing same
GB0417263D0 (en) Process and system
GB0306657D0 (en) Process and compounds
AU2003210518A1 (en) Molecules for diagnostics and therapeutics
GB0317393D0 (en) Process and compounds
GB2401864B (en) Process and catalytic composition
AU2002305913A1 (en) Molecules for diagnostics and therapeutics
GB0209040D0 (en) Improvements in diagnostics
AU4175401A (en) Molecules for diagnostics and therapeutics
AU8696401A (en) Molecules for diagnostics and therapeutics
AU2003231740A8 (en) Compositions and methods for diagnostics and therapeutics for hydrocephalus
GB0306185D0 (en) Molecules
GB0227026D0 (en) Psoriasis diagnostics and therapeutics
HU0304025D0 (en) New process and new intermediate

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase